Antibody drugs conjugates in small-cell lung cancer: present-day status and promises
While ADCs have generated encouraging response rates in SCLC, durability has remained limited. Future development will require optimization of payloads, linkers, and trial design to determine whether ADCs can achieve a sustained role in this disease.
Authors
- Jorge Gómez (ORCID: https://orcid.org/0000-0001-6859-363X)
- May‐Lucie Meyer (ORCID: https://orcid.org/0000-0003-2091-9578)
- Kenneth Angelino
- Fred R. Hirsch (ORCID: https://orcid.org/0000-0002-6885-1894)
- Triparna Sen
- Arjun Syal
- Noah Osei
Institutions
- Mount Sinai Hospital (US)
- The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (US)
- Centre Hospitalier Universitaire Vaudois (CH)
- Tisch Hospital (US)
- The Ohio State University (US)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- The Oncologist
- Published
- 2025-10-04
- DOI
- https://doi.org/10.1093/oncolo/oyaf332
- Primary Topic
- Lung Cancer Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00